The G20210A mutation does not affect the stability of prothrombin mRNA in vivo

Blood

Volumn 100, Issue 1, 2002, Pages 359-362

  Pollak, Eleanor S ^a,b   Lam, Ho Sun ^a,b   Eric Russell, J ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTHROMBIN;

ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; LIVER; POLYADENYLATION; PRIORITY JOURNAL; RNA STABILITY;

EID: 0036660170     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0412     Document Type: Article

References (25)

1. Poort S, Rosendaal F, Reitsma P, Bertina R. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
2. Rosendaal F, Doggen C, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706-708.
3. Degan S, MacGillivray R, Davie E, Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry. 1983;22:2087-2097.
4. Soria J, Almasy L, Souto J, et al. Linkage analysis demonstrates that the prothrombotic G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood. 2000;95:2780-2785.
5. Franco R, Trip M, ten Cate H, et al. The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol. 1999;104:50-54.
6. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci P. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793-1797.
7. Watzke H, Schuttrumpf J, Graf S, Huber K, Panzer S. Increased prevalence of polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res. 1997;87:521-526.
8. Burzotta F, Paciaroni K, DeStefano V, et al. Increased prevalence of the G20210A prothrombin gene variant in adult coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J. 2002;23:26-30.
9. Rosendaal F, Siscovick D, Schwartz S, Psaty B, Raghunathan T, Vos H. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
10. Kupferminc M, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with interuterine growth retardation, abruptio placentae, and second trimester loss. Acta Obstet Gynecol Scand. 2000;79:963-967.
11. Mercier E, Quere I, Campello C, Mares P, Gris J. The 20210A allele of the prothrombin gene is frequent in young women with unexplained spinal cord infarction. Blood. 1998;92:1840-1841.
12. Gehring N, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001;28:389-392.
13. Carter AM, Maurer F, Medcalf RL. The relationship between the prothrombin G20210A polymorphism and prothrombin mRNA stability, XVIIth Congress of the International Society on Thrombosis and Haemostasis. Washington, DC; 1999.
14. Hehlgans S, von der Ahe D, Dohner U, Unkrig C, Potzsch B. Turnover of prothrombin mRNA is not influenced by the 20210A polymorphism. XVIIth Congress of the International Society on Thrombosis and Haemostasis. Washington, DC; 1999.
15. Weiss IM, Liebhaber SA. Erythroid cell-specific determinants of α-globin mRNA stability. Mol Cell Biol. 1994;14:8123-8132.
16. Frank T, Svoboda-Newman M, Hsi E. Comparison of methods for extracting DNA from formalin-fixed paraffin sections for nonisotopic PCR. Diagn Mol Pathol. 1996;5:220-224.
17. Poort S, Bertina R, Vos H. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost. 1997;78:1157-1158.
18. Danneberg J, Abbes A, Bruggeman B, Engel H, Gerritis J, Martens A. Reliable genotyping of the G20210A mutation of coagulation factor II (prothrombin). Clin Chem. 1998;44:349-351.
19. Morales J, Russell JE, Liebhaber SA. Destabilization of human α-globin mRNA by translation anti-termination is controlled during erythroid terminal differentiation and paralleled by phased shortening of the poly(A) tail. J Biol Chem. 1997;272:6607-6613.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
21. Searfoss A, Dever T, Wickner R. Linking the 3′ poly(A) tail to the subunit joining step of translation initiation: relations of Pab1p, eukaryotic translation initiation factor 5b (Fun12p), and Ski2p-Slh1p. Mol Cell Biol. 2001;21:4900-4908.
22. Wakiyama M, Honkura N, Miura K. Interference with interaction between eukaryotic translation initiation factor 4G and poly(A) binding protein in Xenopus oocytes leads to inhibition of polyadenylated mRNA translation and oocyte maturation. J Biochem. 2001;130:737-740.
23. Zilka A, Garlapati S, Dahan E, Yaolsky V, Shapira M. Developmental regulation of heat shock protein 83 in Leishmania. 3′ processing and mRNA stability control transcript abundance, and translation is directed by a determinant in the 3′-untranslated region. J Biol Chem. 2001;276:47988-47929.
24. Munroe D, Jacobson A. mRNA poly(A) tail, a 3′ enhancer of translation initiation. Mol Cell Biol. 1990;10:3441-3455.
25. Doolittle R. The evolution of vertebrate blood coagulation: a case of Yin and Yang. Thromb Haemost. 1993;70:24-28.